The Therapeutic Effects of Specific CDK4/6-Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer

Luis Mendoza


Dysregulation of the cyclin D1-CDK4/6-RB pathways results in increased proliferation, and frequently observed in many types of cancer. Due to the importance of the CDK4/6 activity in cancer cells, CDK4/6 inhibitors have emerged as promising candidates for cancer treatment especially for hormonal receptor–positive (HR+) breast cancer patients to help to overcome the acquired or de novo hormonal treatment resistance.  In particular, the combination of CD4/6 inhibitors with endocrine therapy in first-line and after hormonal failure is expected to transform the treatment of HR+ breast cancer. Currently, three selective CD4/6 inhibitors have been approved or are in the late phase of development. Here we describe the efficacy and safety from the most relevant clinical data for these novel agents.

Klíčová slova

breast cancer – CDK4/6 inhibitors – hormone receptor-positive – palbociclib – ribociclib – abemaciclib

Full Text:

PDF (English)

Na tento článek odkazuje

  • Aktuálně neexistují žádné citace.